Werewolf Therapeutics近日通过美国证券交易委员会（SEC）文件正式披露，已从EMD手中获得关于WTX-124和WTX-330两款候选药物的独家开发许可。这一战略举措标志着该公司在肿瘤免疫治疗领域的布局进一步深化。
根据文件内容，此次授权涵盖了两款药物的研发权益，为Werewolf Therapeutics提供了更为广阔的创新空间。公司方面表示，这一合作将有助于加速相关项目的临床推进，并有望为患者带来新的治疗选择。
值得注意的是，WTX-124和WTX-330均为公司管线中的重要资产，此次获得独家授权后，Werewolf Therapeutics将拥有更大的自主权来主导后续的开发工作。市场分析人士认为，这一动作不仅增强了公司的研发实力，也为其长期价值增添了新的看点。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.